Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology
Release Date: 06/25/2024
New Hepatitis B Oral Treatment Blocks Viral Integration and Progression with Lawrence Blatt Aligos Therapeutics TRANSCRIPT
Empowered Patient Podcast
Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics, describes the current gaps in treating the hepatitis B virus and how the disease can potentially lead to end-stage liver disease and liver cancer. Current therapies were initially developed for HIV and can suppress the virus but not eliminate or prevent the disease. The lead Aligos drug candidate blocks all steps of viral replication and prevents the virus from integrating into infected liver cells, where it can activate cancer-causing genes. Lawrence explains, "Hepatitis B virus is actually the most prevalent chronic...
info_outline
New Hepatitis B Oral Treatment Blocks Viral Integration and Progression with Lawrence Blatt Aligos Therapeutics
Empowered Patient Podcast
Lawrence Blatt, Chairman, President, and CEO of Aligos Therapeutics, describes the current gaps in treating the hepatitis B virus and how the disease can potentially lead to end-stage liver disease and liver cancer. Current therapies were initially developed for HIV and can suppress the virus but not eliminate or prevent the disease. The lead Aligos drug candidate blocks all steps of viral replication and prevents the virus from integrating into infected liver cells, where it can activate cancer-causing genes. Lawrence explains, "Hepatitis B virus is actually the most prevalent chronic...
info_outline
Reality Check from Biotech Leaders on Using AI in Drug Discovery with BioXcel Therapeutics Gain Therapeutics iBio TRANSCRIPT
Empowered Patient Podcast
This roundtable on the role of AI in the biotech sector features Frank Yocca, Senior VP and Chief Scientific Officer at BioXcel Therapeutics, Joanne Taylor, Senior VP for Research at Gain Therapeutics, and Martin Brenner, CEO and Chief Scientific Officer at iBio. The conversation covers the historical adoption of AI in biotech, its current use in drug discovery, and future possibilities. AI is not a new phenomenon in biotech and has evolved from data processing to sophisticated models that can screen vast amounts of data. There is a critical need for high-quality, structured data to...
info_outline
Reality Check from Biotech Leaders on Using AI in Drug Discovery with BioXcel Therapeutics Gain Therapeutics iBio
Empowered Patient Podcast
This roundtable on the role of AI in the biotech sector features Frank Yocca, Senior VP and Chief Scientific Officer at BioXcel Therapeutics, Joanne Taylor, Senior VP for Research at Gain Therapeutics, and Martin Brenner, CEO and Chief Scientific Officer at iBio. The conversation covers the historical adoption of AI in biotech, its current use in drug discovery, and future possibilities. AI is not a new phenomenon in biotech and has evolved from data processing to sophisticated models that can screen vast amounts of data. There is a critical need for high-quality, structured data to...
info_outline
Developing Multi-Antigen Vaccines for Immunocompromised Patients with David Dodd GeoVax TRANSCRIPT
Empowered Patient Podcast
David Dodd, CEO of GeoVax, highlights the need for next-generation vaccines, specifically multi-antigen and T cell-focused technologies, to provide better protection for immunocompromised populations. Their pipeline includes a COVID-19 vaccine candidate, an Mpox/Smallpox vaccine, and a gene therapy for solid tumors. A priority for GeoVax is to develop new manufacturing processes to significantly accelerate vaccine production, increase yield, and reduce costs. David explains, "Multi-antigen vaccines become critically important, especially for populations for whom the existing approach in...
info_outline
Developing Multi-Antigen Vaccines for Immunocompromised Patients with David Dodd GeoVax
Empowered Patient Podcast
David Dodd, CEO of GeoVax, highlights the need for next-generation vaccines, specifically multi-antigen and T cell-focused technologies, to provide better protection for immunocompromised populations. Their pipeline includes a COVID-19 vaccine candidate, an Mpox/Smallpox vaccine, and a gene therapy for solid tumors. A priority for GeoVax is to develop new manufacturing processes to significantly accelerate vaccine production, increase yield, and reduce costs. David explains, "Multi-antigen vaccines become critically important, especially for populations for whom the existing approach in...
info_outline
Virtual Support Groups Remove Barriers Encourage Sharing Honest Experiences to Fight Misinformation with Rick Davis AnCan TRANSCRIPT
Empowered Patient Podcast
Rick Davis, patient advocate and Founder of AnCan, is building and operating virtual peer-to-peer support groups to allow patients to connect with others who have direct experience with their condition. These groups can provide accurate information, foster connections among participants, and serve as a check on medical misinformation. With the growing acceptance of virtual meetings, this approach overcomes geographic, physical, and psychosocial barriers that might otherwise prevent participants from attending on-site meetings. Rick explains, "The mission is to make each person and each...
info_outline
Virtual Support Groups Remove Barriers Encourage Sharing Honest Experiences to Fight Misinformation with Rick Davis AnCan
Empowered Patient Podcast
Rick Davis, patient advocate and Founder of AnCan, is building and operating virtual peer-to-peer support groups to allow patients to connect with others who have direct experience with their condition. These groups can provide accurate information, foster connections among participants, and serve as a check on medical misinformation. With the growing acceptance of virtual meetings, this approach overcomes geographic, physical, and psychosocial barriers that might otherwise prevent participants from attending on-site meetings. Rick explains, "The mission is to make each person and each...
info_outline
Healthcare Plans Using Analytics to Improve Health Literacy Patient Engagement and Outcomes with Bob Farrell mPulse TRANSCRIPT
Empowered Patient Podcast
Bob Farrell, CEO of mPulse, is using digital technology, data analytics and AI to improve the relationship between health plans and their members in order to improve health outcomes and operational efficiency. Bob introduces the concept of HXI, Health Experience and Insights, as a framework that unites data, intelligence, and personalized communication to provide tools to enage members at the best time and by the preferred methods with appropriate information at the right time. Analyzing claims data enables plans to identify high-risk patients, promote preventive care, and build health...
info_outline
Healthcare Plans Using Analytics to Improve Health Literacy Patient Engagement and Outcomes with Bob Farrell mPulse
Empowered Patient Podcast
Bob Farrell, CEO of mPulse, is using digital technology, data analytics and AI to improve the relationship between health plans and their members in order to improve health outcomes and operational efficiency. Bob introduces the concept of HXI, Health Experience and Insights, as a framework that unites data, intelligence, and personalized communication to provide tools to enage members at the best time and by the preferred methods with appropriate information at the right time. Analyzing claims data enables plans to identify high-risk patients, promote preventive care, and build health...
info_outlineDr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence.
Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting."
"That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent."
"There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal."
#KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML
